Fertility warning
This medicine may affect fertility.
Leaflet ORSERDU 86mg film-coated tablets
- Product code:
- W71459001
- Quantity:
- 28
- Indicated for:
- breast cancer
- Route of administration:
- oral
- Substance:
- elacestrant (antineoplastic agent)
- ATC
- L02BA04 — Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Anti-estrogens
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Elacestrant is a medication used in the treatment of certain types of breast cancer, especially in postmenopausal women with hormone receptor-positive tumors. This medicine works by blocking estrogen receptors, thereby reducing the stimulation of hormone-dependent cancer cells. Elacestrant may be recommended when other hormonal therapies are no longer effective.
Elacestrant is usually administered as tablets, according to the oncologist’s instructions. The dose and duration of treatment are determined individually, based on the patient’s general condition and response to therapy. It is important to take the medication regularly and not to stop treatment without medical advice.
Side effects may include nausea, fatigue, headaches, hot flashes, or digestive disturbances. In some cases, changes in blood test results or allergic reactions may occur. If unusual or severe symptoms appear, it is recommended to contact your doctor immediately.
Elacestrant provides an additional option for patients with advanced breast cancer, helping to slow disease progression. Careful monitoring and constant communication with the medical team are essential for the safety and effectiveness of the treatment.
Elacestrant is usually administered as tablets, according to the oncologist’s instructions. The dose and duration of treatment are determined individually, based on the patient’s general condition and response to therapy. It is important to take the medication regularly and not to stop treatment without medical advice.
Side effects may include nausea, fatigue, headaches, hot flashes, or digestive disturbances. In some cases, changes in blood test results or allergic reactions may occur. If unusual or severe symptoms appear, it is recommended to contact your doctor immediately.
Elacestrant provides an additional option for patients with advanced breast cancer, helping to slow disease progression. Careful monitoring and constant communication with the medical team are essential for the safety and effectiveness of the treatment.
General data about ORSERDU 86mg
- Substance:
- elacestrant
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W71459001
- Concentration:
- 86mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 28
- Product type:
- Generic medicine
- Price:
- 14474.80 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for elacestrant
- 345mg
- 86mg